BR9507672A - Derivados tricíclicos de dicarbonila - Google Patents

Derivados tricíclicos de dicarbonila

Info

Publication number
BR9507672A
BR9507672A BR9507672A BR9507672A BR9507672A BR 9507672 A BR9507672 A BR 9507672A BR 9507672 A BR9507672 A BR 9507672A BR 9507672 A BR9507672 A BR 9507672A BR 9507672 A BR9507672 A BR 9507672A
Authority
BR
Brazil
Prior art keywords
lower alkyl
pct
disease
amino
signify
Prior art date
Application number
BR9507672A
Other languages
English (en)
Inventor
Bernd Buettelmann
Thierry Godel
Laurence Gross
Marie-Paule Heitz Neidhart
Claus Riemer
Rene Wyler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR9507672A publication Critical patent/BR9507672A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR9507672A 1994-05-24 1995-05-16 Derivados tricíclicos de dicarbonila BR9507672A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH160294 1994-05-24
CH47795 1995-02-17
PCT/EP1995/001856 WO1995032205A1 (en) 1994-05-24 1995-05-16 Tricyclic dicarbonyl derivatives

Publications (1)

Publication Number Publication Date
BR9507672A true BR9507672A (pt) 1997-08-19

Family

ID=25684688

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9507672A BR9507672A (pt) 1994-05-24 1995-05-16 Derivados tricíclicos de dicarbonila

Country Status (16)

Country Link
US (1) US5688803A (pt)
EP (1) EP0760819B1 (pt)
JP (1) JP2828506B2 (pt)
CN (1) CN1044245C (pt)
AT (1) ATE194841T1 (pt)
AU (1) AU688515B2 (pt)
BR (1) BR9507672A (pt)
CA (1) CA2189776A1 (pt)
DE (1) DE69518075T2 (pt)
DK (1) DK0760819T3 (pt)
ES (1) ES2149989T3 (pt)
GR (1) GR3034625T3 (pt)
NZ (1) NZ287413A (pt)
PT (1) PT760819E (pt)
RU (1) RU2145606C1 (pt)
WO (1) WO1995032205A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5243049A (en) * 1992-01-22 1993-09-07 Neurogen Corporation Certain pyrroloquinolinones: a new class of GABA brain receptor ligands
US5955465A (en) * 1996-03-22 1999-09-21 Neurogen Corporation 1,2,4-triazolo 4,3-c!quinazolin-3-ones and 1,2,4-triazolo 4,3-c!quinazolin-3-thiones
GB2346883B (en) * 1996-09-02 2001-02-14 Lilly Industries Ltd GluR5 receptor binding assay
FR2773153A1 (fr) * 1997-12-29 1999-07-02 Rhone Poulenc Agrochimie Nouveaux composes fongicides
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
AU2220801A (en) * 1999-12-22 2001-07-03 Kyorin Pharmaceutical Co. Ltd. Tricyclic compounds and addition salts thereof
DE10004572A1 (de) * 2000-02-02 2001-08-09 Boehringer Ingelheim Pharma Neue positive allosterische AMPA-Rezeptor Modulatoren (PAARM), Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
GB0223730D0 (en) * 2002-10-11 2002-11-20 Novartis Ag Organic compounds
EP1719771A1 (en) 2004-02-19 2006-11-08 Takeda Pharmaceutical Company Limited Pyrazoloquinolone derivative and use thereof
JO3077B1 (ar) * 2005-07-28 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينولين مضادة للبكتيريا
TW200806670A (en) * 2006-04-25 2008-02-01 Merck & Co Inc Inhibitors of checkpoint kinases
US7907679B2 (en) * 2007-01-12 2011-03-15 General Dynamics C4 Systems, Inc. Methods and systems for acquiring signals using coherent match filtering
US8139680B2 (en) 2007-01-12 2012-03-20 General Dynamics C4 Systems, Inc. Signal acquisition methods and apparatus in wireless communication systems
WO2008109613A1 (en) * 2007-03-05 2008-09-12 Wyeth Benzo[c][2,7]naphthyridine derivatives, and their use as kinase inhibitors
WO2008154447A1 (en) * 2007-06-08 2008-12-18 Helicon Therapeutics, Inc. Therapeutic pyrazolonaphthyridine derivatives
WO2009123537A1 (en) * 2008-04-04 2009-10-08 Forskarpatent I Syd Ab GABAa RECEPTOR MODULATORS
DE102008022221A1 (de) 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
WO2009139916A1 (en) * 2008-05-16 2009-11-19 Synta Pharmaceuticals Corp. Tricyclic triazole compounds that modulate hsp90 activity
EP2303890A4 (en) * 2008-06-19 2012-04-11 Progenics Pharm Inc INHIBITORS OF PHOSPHATIDYLINOSITE-3-KINASE
JP5362839B2 (ja) 2008-11-14 2013-12-11 エフ.ホフマン−ラ ロシュ アーゲー Nk3受容体アンタゴニストとしてのキナゾリン誘導体
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
WO2011146591A1 (en) 2010-05-19 2011-11-24 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
EP2861071B1 (en) 2012-04-04 2017-03-15 Merck Sharp & Dohme Corp. Aldosterone synthase inhibitors
EP2929169B1 (en) 2012-12-04 2019-02-13 Volvo Truck Corporation Method and system for controlling fuel injection
CN103073547A (zh) * 2013-02-06 2013-05-01 上海药明康德新药开发有限公司 一种(3aS,9bR)-叔丁基-3,3a,4,5-四氢吡咯[3,4-c]喹啉-2(9bH)酯的合成方法
EP2982675B1 (en) 2013-04-05 2017-08-16 Eisai R&D Management Co., Ltd. Salt of pyrazoloquinoline derivative, and crystal thereof
AU2014250391B2 (en) 2013-04-05 2017-11-02 Eisai R&D Management Co., Ltd. Pyridinylpyrazoloquinoline compound
CN104447736B (zh) * 2014-10-14 2016-06-08 雅安职业技术学院 一种veranamine的合成方法
RU2019135261A (ru) 2017-06-01 2021-07-09 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Фармацевтическая композиция, содержащая ингибитор pde9
CN110603039B (zh) 2017-06-01 2023-02-28 卫材R&D管理有限公司 组合吡唑并喹啉衍生物和美金刚的痴呆治疗剂
AU2018278422B2 (en) 2017-06-01 2022-03-17 Eisai R&D Management Co., Ltd. Lewy body disease therapeutic agent containing pyrazoloquinoline derivative
JP7079777B2 (ja) 2017-06-01 2022-06-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロキノリン誘導体とドネペジルの併用による認知症治療剤
WO2024012554A1 (zh) * 2022-07-14 2024-01-18 上海日馨医药科技股份有限公司 Tpk激动剂及使用其治疗神经退行性疾病的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL66835A (en) * 1981-09-24 1988-05-31 Roussel Uclaf 1,4-disubstituted(1,2,4)triazolo(4,3-alpha)quinazolin-5(4h)-one derivatives and their salts,their preparation and pharmaceutical compositions containing them
US4713383A (en) * 1984-10-01 1987-12-15 Ciba-Geigy Corporation Triazoloquinazoline compounds, and their methods of preparation, pharmaceutical compositions, and uses
DE69113115T2 (de) * 1990-05-31 1996-06-13 Merck Sharp & Dohme Dioxo-tetrahydrochinolinderivate.

Also Published As

Publication number Publication date
ATE194841T1 (de) 2000-08-15
EP0760819B1 (en) 2000-07-19
WO1995032205A1 (en) 1995-11-30
NZ287413A (en) 1998-02-26
CN1149295A (zh) 1997-05-07
DK0760819T3 (da) 2000-10-09
RU2145606C1 (ru) 2000-02-20
AU688515B2 (en) 1998-03-12
AU2613095A (en) 1995-12-18
JP2828506B2 (ja) 1998-11-25
GR3034625T3 (en) 2001-01-31
CA2189776A1 (en) 1995-11-30
ES2149989T3 (es) 2000-11-16
PT760819E (pt) 2000-11-30
DE69518075T2 (de) 2001-03-22
DE69518075D1 (de) 2000-08-24
CN1044245C (zh) 1999-07-21
US5688803A (en) 1997-11-18
JPH09506634A (ja) 1997-06-30
EP0760819A1 (en) 1997-03-12

Similar Documents

Publication Publication Date Title
BR9507672A (pt) Derivados tricíclicos de dicarbonila
CA2783727A1 (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
KR20180095625A (ko) 신규한 화합물
CN108602818B (zh) 吡唑稠环类衍生物、其制备方法及其在治疗癌症,炎症和免疫性疾病上的应用
YU27902A (sh) Derivati benzodiazepina
AU695045B2 (en) Heteroaromatic oxazole compounds and use thereof
CA2386974A1 (en) Benzodiazepine derivatives for use in acute or chronic neurological disorders
WO2001021160B1 (en) Carboxymide and aniline derivatives as selective inhibitors of pathogens
CA2288789A1 (en) Substituted 1,2,4-triazolo[3,4-a]phthalazine derivatives as gaba alpha 5 ligands
AU2003284632A1 (en) Isoquinoline compounds and medicinal use thereof
DE69222096D1 (de) Tetrahydropyrrolo[1,2-a]Pyrazin-4-Spiro-3'-Pyrrolidin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
ATE370735T1 (de) Phenylpyridazinderivate und diese enthaltende arzneimittel
CA2601098A1 (en) Dipyrazoles as central nervous system agents
CA2036163C (en) Novel beta-lactam compounds and their production
DE69415341D1 (de) Kondensierte tricyclische heteroaromatische derivate als liganden des dopamin-rezeptor-subtyps
TR199900946T2 (xx) 2-Metoksifenilpiperazin t�revleri.
JO2307B1 (en) Papermidine derivatives
BR0213177A (pt) Derivados de 5-metóxi-8-aril-[1,2,4]triazolo[1,5-a]piridina
EP1557414A4 (en) ISOQUINOLINE COMPOUNDS AND THEIR MEDICINAL USE
JPWO2002042312A1 (ja) 新規カルバペネム誘導体
WO2001007023A3 (en) Azetidine compounds in cns and eye diseases
IE67525B1 (en) Derivatives of Penem
ES2112470T3 (es) Derivados de piridazinona, procedimientos de produccion y utilizacion.
WO2001007022A3 (en) Azetidine compounds in cns and eye diseases

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
HJEG Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law
FF Decision: intention to grant
FG9A Patent or certificate of addition granted
B24C Patent annual fee: request for for restoration

Free format text: REFERENTE A 13A,14A,15A E 16A ANUIDADES

B24H Lapse because of non-payment of annual fees (definitively: art 78 iv lpi)
B24F Patent annual fee: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 24.8 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE AS 13A, 14A, 15A E 16A ANUIDADES.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2607 DE 22-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.